Document is current
Any future updates will be listed below
-
Authors
Taskindoust, Mahsa
Thomas, Samantha M.
Sammons, Sarah L.
Fayanju, Oluwadamilola M.
DiLalla, Gayle
Hwang, E. Shelley
Plichta, Jennifer K. https://orcid.org/0000-0002-7411-0558
-
Funding
Funding for this research was provided by:
National Institute of Health (P30CA014236)
- License Information
-
More Information
Article History
Received: 19 March 2021
Accepted: 6 May 2021
First Online: 28 May 2021
Disclosures
: The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article. Dr. J. Plichta is a recipient of research funding by the Color Foundation (PI: Plichta). She serves on the NCCN Breast Cancer Screening Committee and the ASCO Clinical Practice Guideline Committee for the Management of Male Breast Cancer. Dr. E.S. Hwang serves on the NCI Breast Cancer Steering Committee and the NCCN Breast Cancer Prevention Committee. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Samantha Thomas had a consulting relationship with Abbvie, Inc. on work in bioequivalence. This relationship ended in January 2019 and was unrelated to this work. Cancer Center Support Grant P30 from NCI provided funding for statistical support. Sarah L. Sammons reports research funding from Abbvie, Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Sermonix. Advisory to Astra Zeneca, Daiichi Sankyo, Foundation Medicine, Novartis.
